Drugs / CD30.CAR-EBVST cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04952584 | Mar 2024 → Jun 2025 | classic Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma | Baylor College of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04288726 | Sep 2020 → Jun 2027 expected | classic Hodgkin lymphoma, extranodal nasal NK/T cell lymphoma | Baylor College of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD30.CAR-EBVST cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04288726 ↗ |
| Modality | Cell therapy | “infusion with CD30.CAR-EBVST cell treatment” NCT04288726 ↗ |
| Route | Intravenous | “The CD30.CAR-EBVST cells will be infused via an IV line at the assigned dose.” NCT04288726 ↗ |